If Zantac resolved I am looking for £25. Yield here still good for a pharma and should be rising hence my recent buys and plan to add further still for a long term investment |
I think we can be ambitious for more than £18 IF the court cases are resolved satisfactorily |
Not until the court cases are over and out. |
1800 shortly imo |
UK market is massively underperforming every single day. Look at the DAX again despite a ruined German economy. I stick to what I say irrelevant of the performance of a single current darling stock |
 GSK plc (LSE/NYSE: GSK) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted SENKU (formerly known as SAKIGAKE) designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). SENKU designation is granted based on the level of innovation, severity of disease, and prominent efficacy. The goal of SENKU designation is to increase early patient access to innovative medicines through an expedited review process to treat serious conditions and fill an unmet medical need.
The designation is based on results from the phase IIb B-Clear and B-Sure trials which evaluated the efficacy, safety and durability of response of bepirovirsen in people with CHB. A confirmatory phase III programme, B-Well, is ongoing. This is the second regulatory designation in 2024 for bepirovirsen, following the US Food and Drug Administration (FDA) Fast Track designation for bepirovirsen granted earlier this year.
Further information is available at: hxxps://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b. |
GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients, limited to those who are inadequately controlled with standard treatment.
Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D, at GSK said: "The chronic and debilitating impact that chronic rhinosinusitis with nasal polyps can have on those affected is often underestimated. This additional indication for Nucala in Japan could provide patients with an alternative treatment option to surgery or systemic steroids." |
GSK PLC (LSE:GSK, NYSE:GSK) shares opened higher after Delaware's Supreme Court said it will hear an appeal by the UK drug maker and other pharmaceutical companies, including Pfizer, Sanofi, and Boehringer Ingelheim, to dismiss over 70,000 lawsuits alleging that the discontinued heartburn drug Zantac causes cancer.
The companies argue that the scientific methods used by plaintiffs to link Zantac to cancer are unsound. |
Even a barrage of good news only lifts the shareprice by 1% ... |
The strong pound not hitting AZN, thats a poor excuse, as it keeps hitting ATH... |
The strong £ is not helping and nor is the anticipation of everyone getting fleeced in the budget |
The yanks are a jealous lot and can't digest anyone's success specially the British,they are not going to quit. |
This company really can't catch a break from the market... |
This is the UK mkt though..... |
Yes a positive Zantac development but it's not over yet.
And who trusts US courts......
Suet |
You'd think! |
Three positive RNS today, should be a decent day for GSK 👊 |
Company RNS out to confirm the same .. |
Looking at the volume and 3.7% increase in the price yesterday in the US listed stock, the Americans seem confident |
Wasn't aware but definitely positive. The Delaware judge went against the flow of legal opinion to date and the fact that they allowing the appeal to be heard implies they know this. |
Surprised by the lack of comment here, on ADVFN, regarding this... |
about time it turned around then |
GSK unperformed for 2 decades . Pleased to be out of it . |
GSK have traded sideways for 20-25 years now, and on a small PE of 16..
In contrast AZN have gone from 20 quid to 130 and trading on a PE of 41
IF the Zantac wins stack up, it does make an awkward precedent for other judges to rule against us, we could see 1800 again by year end for starters, with plenty of headroom..
Nice to see HLN up from 275-375 for free too, a small dividend there but it is ramping up slowly as the debt winds off.. :o) |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
